The landscape in medtech investing is changing, and one need only look at two signposts to see that this is so: the exit values of VC-backed companies over the past eight years (lower than anticipated), and the amount of time required to achieve those exits (longer than ever before). De Novo Ventures' Richard Ferrari presents the trends that emerge from eight years of venture investing in medical technology companies.
by Richard M. Ferrari
Over the last four years the amount of capital flowing into the health care sector has remained robust—in fact, it’s at an all time high, and that has many venture...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
